The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system

Journal of Biological Chemistry

Volumn 287, Issue 53, 2012, Pages 44628-44644

  García Huerta, Paula ^a,b   Diáz Hernandez, Miguel ^a,b   Delicado, Esmerilda G ^a,b   Pimentel Santillana, María ^c   Miras Portugals, MaTeresa ^a,b   Goḿez Villafuertes, Rosa ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROCESS; CORTICAL NEURONS; ENHANCED GREEN FLUORESCENT PROTEIN; KEY ELEMENTS; MITHRAMYCIN; NEUROBLASTOMA CELLS; OVER-EXPRESSION; PHYSIOLOGICAL FUNCTIONS; PRIMARY CULTURE; PROTEIN FACTORS; RECEPTOR EXPRESSION; RECEPTOR LEVELS; SITE DIRECTED MUTAGENESIS; SP1 BINDING SITES; SPECIFICITY PROTEIN 1; TRANSCRIPTIONAL ACTIVATIONS; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; UP-REGULATION;

MAMMALS; TRANSCRIPTION FACTORS;

CELL CULTURE;

ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; MITHRAMYCIN; PURINERGIC P2X7 RECEPTOR; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BINDING SITE; BRAIN CELL; BRAIN LEVEL; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE LOCATION; GENE OVEREXPRESSION; GENE SILENCING; INHIBITION KINETICS; MACROPHAGE; MALE; MOLECULAR DYNAMICS; MOUSE; NERVOUS SYSTEM; NEUROBLASTOMA CELL; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PURINERGIC P2X7 RECEPTOR GENE; REGULATOR GENE; SITE DIRECTED MUTAGENESIS; TATA BOX; TRANSCRIPTION FACTOR SP1 GENE; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; BRAIN; FEMALE; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVOUS SYSTEM; NEURONS; PROMOTER REGIONS, GENETIC; RECEPTORS, PURINERGIC P2X7; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

MAMMALIA; MURINAE; MUS MUSCULUS;

EID: 84871775451     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.390971     Document Type: Article

References (82)

1. Coddou, C., Yan, Z., Obsil, T., Huidobro-Toro, J. P., and Stojilkovic, S. S. (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol. Rev. 63, 641-683
2. Torres, G. E., Egan, T. M., and Voigt, M. M. (1999) Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. J. Biol. Chem. 274, 6653-6659
3. North, R. A. (2002) Molecular physiology of P2X receptors. Physiol. Rev. 82, 1013-1067
4. Burnstock, G., Krügel, U., Abbracchio, M. P., and Illes, P. (2011) Purinergic signalling. From normal behaviour to pathological brain function. Prog. Neurobiol. 95, 229-274
5. León, D., Hervás, C., and Miras-Portugal, M. T. (2006) P2Y1 and P2X7 receptors induce calcium/calmodulin-dependent protein kinase II phosphorylation in cerebellar granule neurons. Eur. J. Neurosci. 23, 2999-3013
6. Ortega, F., Pérez-Sen, R., Delicado, E. G., and Miras-Portugal, M. T. (2009) P2X7 nucleotide receptor is coupled to GSK-3 inhibition and neuroprotection in cerebellar granule neurons. Neurotox Res. 15, 193-204
7. Díaz-Hernandez, M., del Puerto, A., Díaz-Hernandez, J. I., Diez-Zaera, M., Lucas, J. J., Garrido, J. J., and Miras-Portugal, M. T. (2008) Inhibition of the ATP-gated P2X7 receptor promotes axonal growth and branching in cultured hippocampal neurons. J. Cell Sci. 121, 3717-3728
8. Gómez-Villafuertes, R., del Puerto, A., Díaz- Hernández, M., Bustillo, D., Díaz-Hernández, J. I., Huerta, P. G., Artalejo, A. R., Garrido, J. J., and Miras-Portugal, M. T. (2009) Ca2+/calmodulin-dependent kinase II signalling cascade mediates P2X7 receptor-dependent inhibition of neuritogenesis in neuroblastoma cells. FEBS J. 276, 5307-5325
9. Diaz-Hernandez, J. I., Gomez-Villafuertes, R., León-Otegui, M., Hontecillas-Prieto, L., Del Puerto, A., Trejo, J. L., Lucas, J. J., Garrido, J. J., Gualix, J., Miras-Portugal, M. T., and Diaz-Hernandez, M. (2012) In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases. Neurobiol. Aging 33, 1816-1828
10. Díaz-Hernández, M., Díez-Zaera, M., Sánchez-Nogueiro, J., Gómez-Villafuertes, R., Canals, J. M., Alberch, J., Miras-Portugal, M. T., and Lucas, J. J. (2009) Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J. 23, 1893-1906
11. Skaper, S. D., Debetto, P., and Giusti, P. (2010) The P2X7 purinergic receptor. From physiology to neurological disorders. FASEB J. 24, 337-345
12. Tsuda, M., Tozaki-Saitoh, H., and Inoue, K. (2010) Pain and purinergic signaling. Brain Res. Rev. 63, 222-232
13. Raffaghello, L., Chiozzi, P., Falzoni, S., Di Virgilio, F., and Pistoia, V. (2006) The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res. 66, 907-914
14. Di Virgilio, F., Ferrari, D., and Adinolfi, E. (2009) P2X(7). A growth-promoting receptor-implications for cancer. Purinergic Signal 5, 251-256
15. Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., and Buell, G. (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272, 735-738
16. Rassendren, F., Buell, G. N., Virginio, C., Collo, G., North, R. A., and Surprenant, A. (1997) The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J. Biol. Chem. 272, 5482-5486
17. Chessell, I. P., Simon, J., Hibell, A. D., Michel, A. D., Barnard, E. A., and Humphrey, P. P. (1998) Cloning and functional characterization of the mouse P2X7 receptor. FEBS Lett. 439, 26-30
18. Gu, B. J., Zhang, W., Worthington, R. A., Sluyter, R., Dao-Ung, P., Petrou, S., Barden, J. A., and Wiley, J. S. (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J. Biol. Chem. 276, 11135-11142
19. Wiley, J. S., Dao-Ung, L. P., Li, C., Shemon, A. N., Gu, B. J., Smart, M. L., Fuller, S. J., Barden, J. A., Petrou, S., and Sluyter, R. (2003) An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J. Biol. Chem. 278, 17108-17113
20. Gu, B. J., Sluyter, R., Skarratt, K. K., Shemon, A. N., Dao-Ung, L. P., Fuller, S. J., Barden, J. A., Clarke, A. L., Petrou, S., and Wiley, J. S. (2004) An Arg-307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J. Biol. Chem. 279, 31287-31295
21. Skarratt, K. K., Fuller, S. J., Sluyter, R., Dao-Ung, L. P., Gu, B. J., and Wiley, J. S. (2005) A 5′ intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1-2% of the Caucasian population. FEBS Lett. 579, 2675-2678
22. Cabrini, G., Falzoni, S., Forchap, S. L., Pellegatti, P., Balboni, A., Agostini, P., Cuneo, A., Castoldi, G., Baricordi, O. R., and Di Virgilio, F. (2005) A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J. Immunol. 175, 82-89
23. Shemon, A. N., Sluyter, R., Fernando, S. L., Clarke, A. L., Dao-Ung, L. P., Skarratt, K. K., Saunders, B. M., Tan, K. S., Gu, B. J., Fuller, S. J., Britton, W. J., Petrou, S., and Wiley, J. S. (2006) A Thr-357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J. Biol. Chem. 281, 2079-2086
24. Eslick, G. D., Thampan, B. V., Nalos, M., McLean, A. S., and Sluyter, R. (2009) Circulating interleukin-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. Int. J. Cardiol. 137, 81-83
25. Sun, C., Chu, J., Singh, S., and Salter, R. D. (2010) Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function. Purinergic Signal. 6, 31-45
26. Stokes, L., Fuller, S. J., Sluyter, R., Skarratt, K. K., Gu, B. J., and Wiley, J. S. (2010) Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1β secretion. FASEB J. 24, 2916-2927
27. Li, C. M., Campbell, S. J., Kumararatne, D. S., Hill, A. V., and Lammas, D. A. (2002) Response heterogeneity of human macrophages to ATP is associated with P2X7 receptor expression but not to polymorphisms in the P2RX7 promoter. FEBS Lett. 531, 127-131
28. Buell, G. N., Talabot, F., Gos, A., Lorenz, J., Lai, E., Morris, M. A., and Antonarakis, S. E. (1998) Gene structure and chromosomal localization of the human P2X7 receptor. Receptors Channels 5, 347-354
29. Zhou, L., Luo, L., Qi, X., Li, X., and Gorodeski, G. I. (2009) Regulation of P2X(7) gene transcription. Purinergic Signal 5, 409-426
30. Gong, S., Zheng, C., Doughty, M. L., Losos, K., Didkovsky, N., Schambra, U. B., Nowak, N. J., Joyner, A., Leblanc, G., Hatten, M. E., and Heintz, N. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425, 917-925
31. Banker, G., and Goslin, K. (1988) Developments in neuronal cell culture. Nature 336, 185-186
32. Velasco, M., Díaz-Guerra, M. J., Díaz-Achirica, P., Andreu, D., Rivas, L., and Boscá, L. (1997) Macrophage triggering with cecropin A- and melittin-derived peptides induces type II nitric oxide synthase expression. J. Immunol. 158, 4437-4443
33. Marban, C., Suzanne, S., Dequiedt, F., de Walque, S., Redel, L., Van Lint, C., Aunis, D., and Rohr, O. (2007) Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBOJ. 26, 412-423
34. Carrasquero, L. M., Delicado, E. G., Sánchez-Ruiloba, L., Iglesias, T., and Miras-Portugal, M. T. (2010) Mechanisms of protein kinase D activation in response to P2Y(2) and P2X7 receptors in primary astrocytes. Glia 58, 984-995
35. Nicke, A., Kuan, Y. H., Masin, M., Rettinger, J., Marquez-Klaka, B., Bender, O., Górecki, D. C., Murrell-Lagnado, R. D., and Soto, F. (2009) A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J. Biol. Chem. 284, 25813-25822
36. Clark, S. J., Harrison, J., and Molloy, P. L. (1997) Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 195, 67-71
37. Suske, G. (1999) The Sp-family of transcription factors. Gene 238, 291-300
38. Suske, G., Bruford, E., and Philipsen, S. (2005) Mammalian SP/KLF transcription factors. Bring in the family. Genomics 85, 551-556
39. Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., Panther, E., and Di Virgilio, F. (2006) The P2X7 receptor. A key player in IL-1 processing and release. J. Immunol. 176, 3877-3883
40. Christensen, M. A., Zhou, W., Qing, H., Lehman, A., Philipsen, S., and Song, W. (2004) Transcriptional regulation of BACE1, the β-amyloid precursor protein β-secretase, by Sp1. Mol. Cell. Biol. 24, 865-874
41. Pan, Q., Yang, S., Wei, Y., Sun, F., and Li, Z. (2010) SP1 acts as a key factor, contributes to up-regulation of ADAM23 expression under serum deprivation. Biochem. Biophys. Res. Commun. 401, 306-312
42. Nicolás, M., Noé, V., Jensen, K. B., and Ciudad, C. J. (2001) Cloning and characterization of the 5′-flanking region of the human transcription factor Sp1 gene. J. Biol. Chem. 276, 22126-22132
43. Tapias, A., Auriol, J., Forget, D., Enzlin, J. H., Schärer, O. D., Coin, F., Coulombe, B., and Egly, J. M. (2004) Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors. J. Biol. Chem. 279, 19074-19083
44. Jia, Z., Zhang, J., Wei, D., Wang, L., Yuan, P., Le, X., Li, Q., Yao, J., and Xie, K. (2007) Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 67, 4878-4885
45. Sperlágh, B., Vizi, E. S., Wirkner, K., and Illes, P. (2006) P2X7 receptors in the nervous system. Prog. Neurobiol. 78, 327-346
46. Pankratov, Y., Lalo, U., Krishtal, O. A., and Verkhratsky, A. (2009) P2X receptors and synaptic plasticity. Neuroscience 158, 137-148
47. Sperlágh, B., Heinrich, A., and Csölle, C. (2007) P2 receptor-mediated modulation of neurotransmitter release. An update. Purinergic Signal 3, 269-284
48. Abbracchio, M. P., Burnstock, G., Verkhratsky, A., and Zimmermann, H. (2009) Purinergic signalling in the nervous system. An overview. Trends Neurosci. 32, 19-29
49. Ortega, F., Pérez-Sen, R., Morente, V., Delicado, E. G., and Miras-Portugal, M. T. (2010) P2X7, NMDA, and BDNF receptors converge on GSK3 phosphorylation and cooperate to promote survival in cerebellar granule neurons. Cell. Mol. Life Sci. 67, 1723-1733
50. Ortega, F., Pérez-Sen, R., Delicado, E. G., and Teresa Miras-Portugal, M. (2011) ERK1/2 activation is involved in the neuroprotective action of P2Y13 and P2X7 receptors against glutamate excitotoxicity in cerebellar granule neurons. Neuropharmacology 61, 1210-1221
51. Sun, S. H. (2010) Roles of P2X7 receptor in glial and neuroblastoma cells. The therapeutic potential of P2X7 receptor antagonists. Mol. Neurobiol. 41, 351-355
52. Azizkhan, J. C., Jensen, D. E., Pierce, A. J., and Wade, M. (1993) Transcription from TATA-less promoters. Dihydrofolate reductase as a model. Crit. Rev. Eukaryot. Gene Expr. 3, 229-254
53. Tan, N. Y., and Khachigian, L. M. (2009) Sp1 phosphorylation and its regulation of gene transcription. Mol. Cell. Biol. 29, 2483-2488
54. Bird, A. P. (1986) CpG-rich islands and the function of DNA methylation. Nature 321, 209-213
55. Larsen, F., Gundersen, G., Lopez, R., and Prydz, H. (1992) CpG islands as gene markers in the human genome. Genomics 13, 1095-1107
56. Siegfried, Z., Eden, S., Mendelsohn, M., Feng, X., Tsuberi, B. Z., and Cedar, H. (1999) DNA methylation represses transcription in vivo. Nat. Genet. 22, 203-206
57. Liu, Y., Liu, X. S., Wei, L., Altman, R. B., and Batzoglou, S. (2004) Eukaryotic regulatory element conservation analysis and identification using comparative genomics. Genome Res. 14, 451-458
58. Jørgensen, N. R., Husted, L. B., Skarratt, K. K., Stokes, L., Tofteng, C. L., Kvist, T., Jensen, J. E., Eiken, P., Brixen, K., Fuller, S., Clifton-Bligh, R., Gartland, A., Schwarz, P., Langdahl, B. L., and Wiley, J. S. (2012) Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur. J. Hum. Genet. 20, 675-681
59. Fuller, S. J., Stokes, L., Skarratt, K. K., Gu, B. J., and Wiley, J. S. (2009) Genetics of the P2X7 receptor and human disease. Purinergic Signal 5, 257-262
60. Li, C. M., Campbell, S. J., Kumararatne, D. S., Bellamy, R., Ruwende, C., McAdam, K. P., Hill, A. V., and Lammas, D. A. (2002) Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. J. Infect Dis. 186, 1458-1462
61. Bouwman, P., and Philipsen, S. (2002) Regulation of the activity of Sp1-related transcription factors. Mol. Cell. Endocrinol. 195, 27-38
62. Roos, M. D., Su, K., Baker, J. R., and Kudlow, J. E. (1997) O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol. Cell. Biol. 17, 6472-6480
63. Emili, A., Greenblatt, J., and Ingles, C. J. (1994) Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol. Cell. Biol. 14, 1582-1593
64. Koller, C. A., and Miller, D. M. (1986) Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N. Engl. J. Med. 315, 1433-1438
65. Seznec, J., Silkenstedt, B., and Naumann, U. (2011) Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J. Neurooncol. 101, 365-377
66. Adinolfi, E., Raffaghello, L., Giuliani, A. L., Cavazzini, L., Capece, M., Chiozzi, P., Bianchi, G., Kroemer, G., Pistoia, V., and Di Virgilio, F. (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 72, 2957-2969
67. Gutiérrez-Martín, Y., Bustillo, D., Gómez- Villafuertes, R., Sánchez-Nogueiro, J., Torregrosa-Hetland, C., Binz, T., Gutiérrez, L. M., Miras-Portugal, M. T., and Artalejo, A. R. (2011) P2X7 receptors trigger ATP exocytosis and modify secretory vesicle dynamics in neuroblastoma cells. J. Biol. Chem. 286, 11370-11381
68. Chatterjee, S., Zaman, K., Ryu, H., Conforto, A., and Ratan, R. R. (2001) Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol. 49, 345-354
69. Ferrante, R. J., Ryu, H., Kubilus, J. K., D'Mello, S., Sugars, K. L., Lee, J., Lu, P., Smith, K., Browne, S., Beal, M. F., Kristal, B. S., Stavrovskaya, I. G., Hewett, S., Rubinsztein, D. C., Langley, B., and Ratan, R. R. (2004) Chemotherapy for the brain. The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 24, 10335-10342
70. Qiu, Z., Norflus, F., Singh, B., Swindell, M. K., Buzescu, R., Bejarano, M., Chopra, R., Zucker, B., Benn, C. L., DiRocco, D. P., Cha, J. H., Ferrante, R. J., and Hersch, S. M. (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 281, 16672-16680
71. Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., McAlpin, S. E., Cormier, K. A., Smith, K. M., and Ferrante, R. J. (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 103, 19176-19181
72. Stack, E. C., Del Signore, S. J., Luthi-Carter, R., Soh, B. Y., Goldstein, D. R., Matson, S., Goodrich, S., Markey, A. L., Cormier, K., Hagerty, S. W., Smith, K., Ryu, H., and Ferrante, R. J. (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 16, 1164-1175
73. Hagiwara, H., Iyo, M., and Hashimoto, K. (2009) Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine. Brain Res. 1301, 189-196
74. Dunah, A. W., Jeong, H., Griffin, A., Kim, Y. M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243
75. Li, S. H., Cheng, A. L., Zhou, H., Lam, S., Rao, M., Li, H., and Li, X. J. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22, 1277-1287
76. Wang, R., Luo, Y., Ly, P. T., Cai, F., Zhou, W., Zou, H., and Song, W. (2012) Sp1 regulates human huntingtin gene expression. J. Mol. Neurosci. 47, 311-321
77. Engel, T., Gomez-Villafuertes, R., Tanaka, K., Mesuret, G., Sanz-Rodriguez, A., Garcia-Huerta, P., Miras-Portugal, M. T., Henshall, D. C., and Diaz-Hernandez, M. (2012) Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 26, 1616-1628
78. León-Otegui, M., Gómez-Villafuertes, R., Díaz-Hernández, J. I., Díaz-Hernández, M., Miras-Portugal, M. T., and Gualix, J. (2011) Opposite effects of P2X7 and P2Y2 nucleotide receptors on α-secretase-dependent APP processing in Neuro-2a cells. FEBS Lett. 585, 2255-2262
79. Marin, M., Karis, A., Visser, P., Grosveld, F., and Philipsen, S. (1997) Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 89, 619-628
80. Saffer, J. D., Jackson, S. P., and Annarella, M. B. (1991) Developmental expression of Sp1 in the mouse. Mol. Cell. Biol. 11, 2189-2199
81. Yoo, J., Jeong, M. J., Kwon, B. M., Hur, M. W., Park, Y. M., and Han, M. Y. (2002) Activation of dynamin I gene expression by Sp1 and Sp3 is required for neuronal differentiation of N1E-115 cells. J. Biol. Chem. 277, 11904-11909
82. Li, L., and Davie, J. R. (2010) The role of Sp1 and Sp3 in normal and cancer cell biology. Ann. Anat. 192, 275-283